PEPIDH1M vaccine / Annias Immunotherap - LARVOL DELTA

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Katy Peters, MD, PhD | Not yet recruiting ➔ Recruiting

Enrollment open • Brain Cancer • Glioma • Oncology • Solid Tumor • IDH1

ViCToRy: Vorasidenib in Combination with Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Katy Peters, MD, PhD | Trial completion date: Aug 2027 ➔ Aug 2029 | Trial primary completion date: Aug 2025 ➔ Aug 2027

Combination therapy • Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor • IDH1

RESIST: IDH1 Peptide Vaccine for Recurrent Grade II Glioma (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Katy Peters, MD, PhD | Active, not recruiting ➔ Completed

Trial completion • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor